# Cost-effectiveness of CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer: a systematic review and meta-analysis

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/cost-effectiveness-of-cdk4-6-inhibitors-in-hr-her2-metastatic-breast-cancer-a/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Prajakta P. Masurkar,Prachi Prajapati,Joanne Canedo,Swarnali Goswami,Sally Earl,Kaustuv Bhattacharya |
| Citations | 11 |
| DOI | 10.1080/03007995.2024.2402074 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W4402700868 |
| PMID | 39305463 |
| Type | review |
| Year | 2024 |

## Paper authors

- [Prajakta P. Masurkar](https://scholariq.org/researchers/prajakta-p-masurkar/)
- [Swarnali Goswami](https://scholariq.org/researchers/swarnali-goswami/)

## Paper journal

- [Current Medical Research and Opinion](https://scholariq.org/journals/current-medical-research-and-opinion/)

## Paper primary topic

- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)

## Paper topics

- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.